NewYork–Presbyterian Hospital

BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology

Retrieved on: 
Wednesday, July 7, 2021
Health care, Cornell University, Health, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill, TM

The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology.

Key Points: 
  • The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology.
  • To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites.
  • The Northeast is one of the three strategic areas that the Company is focused on in the targeted commercial launch phase.
  • BioSigs PURE EP(tm) technology was installed at New York Presbyterian / Weill Cornell Medical Center in New York, NY, one of the nations most comprehensive, integrated healthcare systems and New Yorks top-ranked hospital for 20 years1.

Weill Cornell Medicine Launches $1.5 Billion "We're Changing Medicine" Campaign with More Than $750 Million in Gifts

Retrieved on: 
Thursday, June 17, 2021
Cornell University, Tompkins County, New York, Satellite campuses, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Ivy League, Weill

Powering the We're Changing Medicine campaign is $215 million in foundational gifts from several of the institution's most longstanding benefactors.

Key Points: 
  • Powering the We're Changing Medicine campaign is $215 million in foundational gifts from several of the institution's most longstanding benefactors.
  • Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University.
  • "This auspicious milestone will embolden Weill Cornell Medicine's distinguished doctors, researchers and trainees to continue their vital mission to change medicine."
  • "Weill Cornell Medicine exemplifies our mission to develop solutions that meet tomorrow's most pressing challenges, and the We're Changing Medicine campaign will ensure long-lasting advances in science and medicine."

Intellihealth Wins AmplifyHer Ventures Investment Competition at Weill Cornell Medicine

Retrieved on: 
Tuesday, May 4, 2021
Technology, Biotechnology, Health, Finance, Consumer, Pharmaceutical, Professional services, Telecommunications, Software, General Health, Hospitals, Internet, Women, Data management, Satellite campuses, Tompkins County, New York, Cornell University, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill, Ivy League, New York state), AmplifyHer Ventures, Intellihealth, AMPLIFYHER VENTURES, INTELLIHEALTH

The competition results were announced at the recent Weill Cornell Medicine Startup Symposium.\nA collaboration between AmplifyHer Ventures and the Weill Cornell Medicine BioVenture eLab, which is part of the Office of BioPharma Alliances and Research Collaborations, the investment competition was designed to highlight the exceptional women innovators at Weill Cornell Medicine and was open to companies across the health care and biopharma sectors that are affiliated with the academic medical institution and have women in key leadership roles.

Key Points: 
  • The competition results were announced at the recent Weill Cornell Medicine Startup Symposium.\nA collaboration between AmplifyHer Ventures and the Weill Cornell Medicine BioVenture eLab, which is part of the Office of BioPharma Alliances and Research Collaborations, the investment competition was designed to highlight the exceptional women innovators at Weill Cornell Medicine and was open to companies across the health care and biopharma sectors that are affiliated with the academic medical institution and have women in key leadership roles.
  • Intellihealth co-founder employee Dr. Katherine Saunders is an assistant professor of clinical medicine at Weill Cornell Medicine and was the first clinical fellow in obesity medicine at its Comprehensive Weight Control Center.\nDr.
  • \xe2\x80\x9cIn assessing the applicants, we immediately recognized that Intellihealth is accurately addressing a real market need.
  • More information and a product demonstration can be found at www.intellihealth.co .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005257/en/\n'

PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog

Retrieved on: 
Wednesday, April 7, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Hospitals, Science, Clinical trials, Cornell University, Ivy League, NewYork–Presbyterian Hospital, Columbia University, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York state)

Recent research also shows these cognitive impairments may persist post-hospitalization and commonly occur in post-COVID long haulers or long COVID patients.

Key Points: 
  • Recent research also shows these cognitive impairments may persist post-hospitalization and commonly occur in post-COVID long haulers or long COVID patients.
  • The full text of the announcement from Akili is as follows:
    Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Treatment for Patients with COVID Brain Fog
    BOSTON April 7, 2021 Akili Interactive (Akili or Company"), today announced collaborations with Weill Cornell Medicine , NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate Akili digital therapeutic AKL-T01 as a treatment for patients with cognitive dysfunction following COVID-19 (also known as COVID brain fog).
  • We look forward to working with leading researchers at Vanderbilt, Weill Cornell and NewYork-Presbyterian to understand and improve COVID-19-related cognitive deficits.
  • It is not intended to be used as a stand-alone therapeutic and is not a substitution for a childs medication.

$5 Million Grant from Mastercard Funds Innovative Diversity Initiatives at Weill Cornell Medicine

Retrieved on: 
Tuesday, March 16, 2021
Cornell University, NewYork–Presbyterian Healthcare System, Healthcare in New York City, NewYork–Presbyterian Hospital, Satellite campuses, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Weill Cornell Graduate School of Medical Sciences, NewYork-Presbyterian Brooklyn Methodist Hospital, NewYork-Presbyterian Lower Manhattan Hospital, Weill Cornell Medical Center, NewYork-Presbyterian Queens

"At Weill Cornell Medicine, we have established diversity and mentorship as chief priorities and fundamental pillars of our institution's mission, developing numerous, robust initiatives geared toward increasing representation and nurturing talent in medicine," saidDr.

Key Points: 
  • "At Weill Cornell Medicine, we have established diversity and mentorship as chief priorities and fundamental pillars of our institution's mission, developing numerous, robust initiatives geared toward increasing representation and nurturing talent in medicine," saidDr.
  • Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine.
  • The doctors and scientists of Weill Cornell Medicinefaculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organizationare engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
  • Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital.

Weill Cornell Medicine Establishes Graduate Programs at Houston Methodist

Retrieved on: 
Friday, February 26, 2021
Satellite campuses, Cornell University, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill, Draft:Gunisha Kaur, James K. Min

NEW YORK and HOUSTON, Feb. 26, 2021 /PRNewswire/ -- In an expansion of its top-ranked biomedical education curricula, Weill Cornell Medicine is launching an additional site for graduate programs at Houston Methodist for the 2021-22 academic year.

Key Points: 
  • NEW YORK and HOUSTON, Feb. 26, 2021 /PRNewswire/ -- In an expansion of its top-ranked biomedical education curricula, Weill Cornell Medicine is launching an additional site for graduate programs at Houston Methodist for the 2021-22 academic year.
  • "This partnership between Weill Cornell Medicine and Houston Methodist allows us to broaden and enrich existing collaborations in research, education and clinical care between our two institutions," said Dr. Barbara Hempstead , dean of the Weill Cornell Graduate School of Medical Sciences and the O. Wayne Isom Professor of Medicine at Weill Cornell Medicine.
  • "We look forward to welcoming our first class of Weill Cornell Medicine doctoral candidates at Houston Methodist."
  • The doctors and scientists of Weill Cornell Medicinefaculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organizationare engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.

Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems

Retrieved on: 
Wednesday, February 10, 2021
Cornell University, NewYork–Presbyterian Healthcare System, Trauma centers, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Houston Methodist Hospital, Weill Cornell Medical Center, Westport, Connecticut, Ivy League, Hospitals, Health sciences

New installations of the PURE EP System will now follow a shorter assessment cycle of 90 days based on favorable data from installation evaluations in 2020.

Key Points: 
  • New installations of the PURE EP System will now follow a shorter assessment cycle of 90 days based on favorable data from installation evaluations in 2020.
  • New clinical sites due to receive BioSigs PURE EP System include New York-Presbyterian/Weill Cornell Medical Center, Michigan MedicineUniversity Hospital (two centers that account for two of the largest EP programs in the country), and Houston Methodist Hospital.
  • More than 500 patient cases have been conducted using the PURE EPSystem by 34 physicians in seven clinical sites to date.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Retrieved on: 
Wednesday, February 3, 2021
Cornell University, Ivy League, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Weill, Healthcare in New York City, New York state), James K. Min

"Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido.

Key Points: 
  • "Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido.
  • Dr. Tagawa is also the principle investigator for the targeted radiopharmaceutical therapy at Weil Cornell and his addition to our advisory board demonstrates our support for this innovative technology."
  • Dr. Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine & Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian Weill Cornell Medical Center.
  • Subsequently, he underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years.

Jeffrey S. Borer, MD, is recognized by Continental Who's Who

Retrieved on: 
Friday, December 18, 2020
V-12 Navy College Training Program, Tompkins County, New York, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Cornell University, Weill, Ivy League

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Jeffrey S. Borer, MD, is being recognized by Continental Who's Who as a Prominent Professor for his remarkable contributions in the field of Medical Research and Education and in acknowledgment for his excellence in healthcare.

Key Points: 
  • NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Jeffrey S. Borer, MD, is being recognized by Continental Who's Who as a Prominent Professor for his remarkable contributions in the field of Medical Research and Education and in acknowledgment for his excellence in healthcare.
  • To prepare for his acclaimed career, Dr. Borer received his baccalaureate degree (in Government) from Harvard and his medical degree from Cornell University Medical College (now Weill Cornell Medicine).
  • The development allowed the unmasking of previously unapparent cardiac disabilities and quantifying their functional severity.
  • A respected voice in his field, Dr. Borer has published more than 500 full-length scientific papers/chapters and eight books.

NewYork-Presbyterian Launches Dalio Center for Health Justice

Retrieved on: 
Tuesday, October 13, 2020
Articles, Health, Finance, Ray Dalio, Health Economics, NewYork–Presbyterian Hospital, Dalio, Health equity

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- NewYork-Presbyterian today launched the Dalio Center for Health Justice, dedicated to understanding and improving health equity, addressing health justice, and driving action that results in measurable improvements in health outcomes for all.

Key Points: 
  • NEW YORK, Oct. 13, 2020 /PRNewswire/ -- NewYork-Presbyterian today launched the Dalio Center for Health Justice, dedicated to understanding and improving health equity, addressing health justice, and driving action that results in measurable improvements in health outcomes for all.
  • The Dalio Center for Health Justice is the result of a $50 million grant from Dalio Philanthropies, whose founder Ray Dalio is a NewYork-Presbyterian Trustee and an important thought partner behind the center.
  • "The COVID-19 pandemic exposed enduring health inequities in a new and alarming way, and the importance of health justice has never been clearer," said Dr. Julia Iyasere, head of the Dalio Center for Health Justice at NewYork-Presbyterian.
  • The Dalio Center for Health Justice will serve as a central resource for health justice, health equity and community-based work, focused on institutional alignment and the achievement of measurable and consequential outcomes.